Clinical Trial Results:
Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)
Summary
|
|
EudraCT number |
2016-001964-13 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
03 Nov 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Oct 2017
|
First version publication date |
20 Oct 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
HAF85
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01838070 | ||
WHO universal trial number (UTN) |
U1111-1127-7211 | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur Korea Ltd
|
||
Sponsor organisation address |
11 fl, 235, Banpo-daero, Seocho-gu Seoul, Korea, Republic of, 137-804
|
||
Public contact |
Global Medical Affairs Rep., Sanofi Pasteur Korea Ltd, 82 22136 9533, RegistryContactUS@sanofipasteur.com
|
||
Scientific contact |
Global Medical Affairs Rep., Sanofi Pasteur Korea Ltd, 82 22136 9533, RegistryContactUS@sanofipasteur.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Nov 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
03 Nov 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the safety of AVAXIM 160U (Hepatitis A vaccine) administered under the routine practice, according to Korea Food and Drug Administration "Basic standard for reexamination of new drug" based on the pharmaceutical law in Korea.
|
||
Protection of trial subjects |
No vaccination was administered during this trial. Subjects in this trial previously received AVAXIM 160U (Hepatitis A vaccine) and safety events occurring within 30 days after vaccination under the routine practice during the 4-year surveillance period is reported here.
|
||
Background therapy |
Not applicable | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
04 Nov 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Korea, Republic of: 614
|
||
Worldwide total number of subjects |
614
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
14
|
||
Adults (18-64 years) |
596
|
||
From 65 to 84 years |
4
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Study subjects were enrolled for a 4-year surveillance period (04 November 2011 to 03 November 2015) at 16 clinic centers in South Korea. | ||||||
Pre-assignment
|
|||||||
Screening details |
A total of 614 subjects whose case report forms were retrieved were included in the safety evaluation. | ||||||
Period 1
|
|||||||
Period 1 title |
4-year surveillance period (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
Not applicable
|
||||||
Arms
|
|||||||
Arm title
|
All subjects | ||||||
Arm description |
Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Avaxim® 160U Injection (Hepatitis A Vaccine)
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||
Routes of administration |
Intramuscular use
|
||||||
Dosage and administration details |
0.5 mL, intramuscular, single injection on Day 0.
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
All subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
All subjects
|
||
Reporting group description |
Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved. |
|
|||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects Reporting Solicited Injection-Site and Systemic Events Following A Single Dose of Avaxim 160U Injection (Hepatitis A Vaccine) [1] | ||||||||||||||||||||||||||||||||||||||||
End point description |
1. Solicited injection site reaction (Pain and Erythema) occurring during 7 days after the AVAXIM 160U administration during the 4-year surveillance period. Grade 3: Pain, Significant, prevents daily activity and Erythema, >100 mm.
2. Solicited systemic adverse reactions (Fever [Temperature], Headache, Myalgia or Arthralgia, Asthenia and Gastro-intestinal disorders) occurring during 7 days after the AVAXIM 160U administration during the 4-year surveillance period. Grade 3: Fever, ≥39.0°C; Headache, Myalgia, Arthralgia, Asthenia, and Gastro-intestinal disorders, Significant, prevents daily activity.
|
||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days after the AVAXIM 160U administration during the 4-year surveillance period.
|
||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses were performed based on the study group and the study vaccine previously administered for this outcome. |
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects Reporting Unexpected Adverse Events Following A Single Dose of Avaxim 160U Injection (Hepatitis A Vaccine) | ||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The number subjects with unsolicited adverse events following a single dose of Avaxim 160 U Injection (Hepatitis A Vaccine) are reported.
|
||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
30 days after the AVAXIM 160U administration during the 4-year surveillance period.
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse event data were collected throughout the 4-year surveillance period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
All subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0.1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Aug 2013 |
Updated inclusion criteria, methods of recruitment, and informed consent forms. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |